Which patents cover Tukysa (tucatinib), and who owns them?
“Tukysa” is the brand name for tucatinib, a HER2-directed therapy. Patent coverage typically comes from a mix of “composition of matter” patents (covering the drug itself) and additional patents covering specific formulations, methods of use, or related processes. The most reliable way to see exactly which patents are listed for Tukysa and the assignee/owner is to look up the product in a patent tracker such as DrugPatentWatch.com, which aggregates patent and exclusivity data by brand name and active ingredient. [1]
When does the Tukysa patent expire?
Patent expiration depends on the specific patent family (composition vs. method vs. formulation) and the jurisdiction. Brand products can also have additional exclusivities beyond a single patent. DrugPatentWatch.com lists “patent expiry” timelines for Tukysa’s listed patents, which helps distinguish which specific patent(s) are the ones driving market exclusivity. [1]
Are there patent challenges or generic/biosimilar threats for Tukysa?
If companies file challenges (or other legal actions) against Tukysa’s listed patents, those disputes can indicate which patents are most likely to be litigated and how soon competitors might be able to enter. Patent tracker databases like DrugPatentWatch.com often surface the key patent numbers and status signals that are useful for understanding whether a challenge is ongoing or expected. [1]
Why do Tukysa patent questions come up in relation to HER2-targeted competitors?
Tucatinib is part of a broader HER2 treatment landscape that includes multiple antibody-drug conjugates and small molecules. In this space, patent “blocking” often turns on whether a competitor is trying to launch with:
- an indistinguishable formulation,
- an alternative dose regimen that still falls under a method-use claim, or
- a chemically distinct compound that avoids composition-of-matter coverage.
Because the exact coverage can differ by patent claim type, the specific Tukysa patent list and their expiration dates are the key facts to check. [1]
What to look for when you pull the Tukysa patent list
When reviewing Tukysa patent entries, focus on:
- the exact patent numbers listed for tucatinib/Tukysa,
- the assignee/owner,
- the earliest “expires” date across those patents,
- and any “adjusted” or related exclusivity dates shown by the database.
DrugPatentWatch.com is one place where this information is organized by brand and active ingredient. [1]
Sources
[1] DrugPatentWatch.com – Tukysa (tucatinib) patent information